JOP20210079A1 - التركيبة القائمة على السيكلوديكسترين لمثبط bcl-2 - Google Patents

التركيبة القائمة على السيكلوديكسترين لمثبط bcl-2

Info

Publication number
JOP20210079A1
JOP20210079A1 JOP/2021/0079A JOP20210079A JOP20210079A1 JO P20210079 A1 JOP20210079 A1 JO P20210079A1 JO P20210079 A JOP20210079 A JO P20210079A JO P20210079 A1 JOP20210079 A1 JO P20210079A1
Authority
JO
Jordan
Prior art keywords
cyclodextrin
pharmaceutical composition
relates
bcl
inhibitor
Prior art date
Application number
JOP/2021/0079A
Other languages
English (en)
Inventor
Jean-Manuel Pean
Thu Thuy Tran
Maia Chanrion
Caroline Chemin
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of JOP20210079A1 publication Critical patent/JOP20210079A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع بتركيبة صيدلانية تحتوي على 5-(5-كلورو -2 -{[(3S)-3-(مورفولين-4-يل ميثيل) -3، 4-ثنائي هيدروأيزوكينولين -2 (1H) -يل] كربونيل} فينيل) andndash;N-(5-سيانو-1، 2-ثنائي ميثيل-1H-بيرول-3-يل)-N-(4-هيدروكسي فينيل)-1، 2-ثنائي ميثيل-1H-بيرول-3-كربوكساميد، المشار إليه هنا باسم and#39;المركب أ and#39;، أو ملح مقبول صيدلانيًا منه ، وسيكلودكسترين. بشكل أكثر تحديدًا، يتعلق الاختراع بتركيبة صيدلانية صلبة تحتوي على المركب أ وسيكلودكسترين ، وتركيبة صيدلانية للإعطاء بالحقن محضرة بواسطة إذابة هذه التركيبة الصيدلانية الصلبة. بالإضافة إلى ذلك، يتعلق الاختراع باستخدام مثل هذه التركيبات لعلاج السرطان.
JOP/2021/0079A 2018-10-31 2021-04-20 التركيبة القائمة على السيكلوديكسترين لمثبط bcl-2 JOP20210079A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753164P 2018-10-31 2018-10-31
PCT/EP2019/079644 WO2020089286A1 (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor

Publications (1)

Publication Number Publication Date
JOP20210079A1 true JOP20210079A1 (ar) 2023-01-30

Family

ID=68536777

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0079A JOP20210079A1 (ar) 2018-10-31 2021-04-20 التركيبة القائمة على السيكلوديكسترين لمثبط bcl-2

Country Status (25)

Country Link
US (1) US20210353633A1 (ar)
EP (1) EP3873529A1 (ar)
JP (1) JP7526175B2 (ar)
KR (1) KR20210102886A (ar)
CN (1) CN112912108A (ar)
AR (1) AR116922A1 (ar)
AU (1) AU2019373373B2 (ar)
BR (1) BR112021007987A2 (ar)
CL (1) CL2021001018A1 (ar)
CO (1) CO2021005221A2 (ar)
CR (1) CR20210210A (ar)
DO (1) DOP2021000073A (ar)
EA (1) EA202191144A1 (ar)
GE (2) GEAP202315618A (ar)
IL (1) IL282688A (ar)
JO (1) JOP20210079A1 (ar)
MX (1) MX2021004864A (ar)
NI (1) NI202100031A (ar)
PE (1) PE20211738A1 (ar)
PH (1) PH12021550878A1 (ar)
PY (1) PY1990875A (ar)
SG (1) SG11202103965TA (ar)
TW (1) TWI738100B (ar)
UY (1) UY38431A (ar)
WO (1) WO2020089286A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188387A1 (en) 2020-07-31 2023-06-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
CN116997544A (zh) 2021-03-24 2023-11-03 法国施维雅药厂 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
WO2014108918A2 (en) * 2013-01-08 2014-07-17 Mylan Laboratories Limited An injectable antifungal formulation
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies

Also Published As

Publication number Publication date
PY1990875A (es) 2020-05-04
DOP2021000073A (es) 2021-11-15
CA3117511A1 (en) 2020-05-07
CL2021001018A1 (es) 2021-11-26
NI202100031A (es) 2021-08-24
EA202191144A1 (ru) 2021-09-27
PH12021550878A1 (en) 2021-10-18
GEAP202315618A (en) 2023-08-10
AU2019373373A1 (en) 2021-05-20
TWI738100B (zh) 2021-09-01
BR112021007987A2 (pt) 2021-08-03
KR20210102886A (ko) 2021-08-20
AR116922A1 (es) 2021-06-30
AU2019373373B2 (en) 2023-09-28
EP3873529A1 (en) 2021-09-08
US20210353633A1 (en) 2021-11-18
GEP20237580B (en) 2023-12-25
CO2021005221A2 (es) 2021-07-19
JP7526175B2 (ja) 2024-07-31
TW202031295A (zh) 2020-09-01
PE20211738A1 (es) 2021-09-06
WO2020089286A1 (en) 2020-05-07
CN112912108A (zh) 2021-06-04
IL282688A (en) 2021-06-30
MX2021004864A (es) 2021-08-11
CR20210210A (es) 2021-05-25
UY38431A (es) 2020-05-29
SG11202103965TA (en) 2021-05-28
JP2022506069A (ja) 2022-01-17

Similar Documents

Publication Publication Date Title
JOP20220155A1 (ar) مشتقات البيرازول مفيدة كعوامل مضادة للسرطان
EP4328229A3 (en) Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
PH12019501685A1 (en) Quinazone compound
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
MX2019013954A (es) Inhibidores covalentes de kras.
JOP20210079A1 (ar) التركيبة القائمة على السيكلوديكسترين لمثبط bcl-2
WO2008004798A8 (en) Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
SA521422467B1 (ar) مركبات هالو-آلِّيلامين واستخدامها
EA201391018A1 (ru) Препараты иммуносупрессантов
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
MX391096B (es) Formulación liposomal.
GEAP202115310A (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND THEIR USE
PH12017501831A1 (en) Pharmaceutical compositions for oral administration
NZ728102A (en) Parasiticidal compositions comprising indole derivatives, methods and uses thereof
WO2013188465A3 (en) Treating drug addiction and preventing drug relapse
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
EP4085911A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION FOR THE TREATMENT OF LIVER CANCER
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
GEP20227372B (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
PH12021550323A1 (en) Dendrimer formulations
NZ760052A (en) Methods of treatment for cystic fibrosis
NZ742220A (en) Pharmaceutical compositions comprising meloxicam